Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

SYRS has been the topic of several other reports. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. HC Wainwright restated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Syros Pharmaceuticals has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Up 1.5 %

Shares of Syros Pharmaceuticals stock opened at $0.24 on Friday. The stock has a market capitalization of $6.44 million, a P/E ratio of -0.08 and a beta of 1.33. Syros Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock’s 50-day simple moving average is $1.51 and its 200 day simple moving average is $3.20.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the business earned ($1.35) EPS. As a group, research analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Jason Haas acquired 45,344 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the purchase, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock worth $206,491 in the last quarter. 12.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after purchasing an additional 163,234 shares during the period. Acadian Asset Management LLC raised its holdings in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares during the last quarter. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the 2nd quarter valued at $109,000. Finally, GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the 3rd quarter worth $34,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.